Kannalife Sciences Announces Feasibility Study With Catalent Pharma Solutions for the Development of a Novel Cannabinoid Therapeutic Agent to Treat CTE and HE

Doylestown, Pennsylvania, UNITED STATES

NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the progress of its ongoing feasibility study being performed by Catalent Pharma Solutions. Kannalife was recently informed that it has received the necessary 2016 quota allotment from the U.S. Drug Enforcement Administration (“DEA”) to import high purity pharmaceutical grade cannabidiol into the U.S.  The purpose of the feasibility study with Catalent is to develop a proprietary drug product formulation with suitable solubility and stability characteristics for IND enabling pre-clinical studies in animals and clinical studies in humans, as part of Kannalife’s ongoing research and development of a cannabinoid therapeutic for the treatment of neurodegenerative diseases, including chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE).

William A. Kinney, Chief Scientific Officer of Kannalife stated, “Catalent is a remarkable company that has been the global leader formulation technologies for more than 80 years – bringing the highest quality controlled and assured pharmaceutical products to the market while solving some of the greatest challenges in bioavailability and development for their clients. We are pleased and fortunate to have had and continue to have the privilege of working with their entire team, all of whom are highly professional, dedicated, focused and determined to bring forth the very best solutions for our target drug candidates.”

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700  people, including over 1,000 scientists , at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com - More products. Better treatments. Reliably supplied.™

About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions.  For more information, visit www.kannalife.com


Contact Data